FDA deems Sanofi/Genzyme drug olipudase alfa 'breakthrough'

The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).

The FDA has granted breakthrough therapy designation (BTD) to an experimental medicine from Sanofi and its US Genzyme unit for olipudase alfa, an experimental enzyme replacement therapy being investigated to treat Niemann-Pick disease type B (NPB).

NPB is a serious and life-threatening disorder caused by insufficient activity of the enzyme acid sphingomyelinase, which results in toxic...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category